Investors and Partners

Q-Sera’s technology is based on intellectual property from The University of Queensland (UQ) Centre for Clinical Research, which was identified and developed by UniQuest, the commercialization company of The University of Queensland.

Q-Sera has the support of leading Australian Investors, Uniseed and Brandon BioCatalyst (formerly known as the Medical Research Commercialization Fund (MRCF)).

About UniQuest

UniQuest is the commercialisation company of The University of Queensland (UQ). In partnership with UQ researchers, we create impact through the commercialisation of UQ intellectual property (IP). Established in 1984, UniQuest’s commercialisation track record positions UQ as the leader of research commercialisation in Australasia. UniQuest has formed more than 125 start-up companies built on UQ IP. These companies have raised more than A$965 million to advance UQ technologies towards the market and have directly created more than 450 new jobs. UniQuest’s track record and notable successes include the blockbuster cervical cancer vaccine GARDASIL^® and start-up companies Spinifex Pharmaceuticals Inc and Inflazome Ltd, which were acquired in two of the largest university start-up exits in Australian history.

Marketed products containing UQ IP licensed by UniQuest have generated gross sales of more than A$57 billion, significantly contributing to societal and economic impact. UniQuest has also established the Queensland Emory Drug Discovery Initiative (QEDDI), a world-class small molecule drug discovery and development group, dedicated to translating academic biomedical research into drug candidates for partnering.

About Uniseed

Uniseed is Australia’s longest running early-stage commercialisation fund that makes investments in research emanating from five of Australia’s leading research organisations – The University of Queensland, The University of Sydney, The University of New South Wales, The University of Melbourne and the CSIRO. Investment capital is provided by these research organisations and leading Australian superannuation fund UniSuper. These research organisations collectively spend $4 billion on research annually, making up over 40% of the total research spend in all research organisations in Australia. The fund facilitates the commercialisation of its research partners’ most promising intellectual property and secures targeted investment in resulting products and technologies. Uniseed has supported 63 start-up companies to date, being the seed investor in most of these and has exited twelve investments, to date. For more information, visit www.uniseed.com

About Brandon Capital and Brandon BioCatalyst

Brandon Capital is Australasia’s leading life science venture capital firm, with an international presence and team members across the US and UK. From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialisation. Our venture model is unique: we don’t just provide investment, we partner with inventors, entrepreneurs and research organisations, providing hands-on support and expertise to increase their chance of success.

Brandon BioCatalyst, Brandon Capital’s Australasian-based collaboration, brings together 50 trans-Tasman medical research institutes, investors, and governments all united in progressing the next generation of medical therapies and technology. Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries associated with member research organisations, providing both capital and expertise to guide the successful development of new therapies.